103 related articles for article (PubMed ID: 17645460)
21. [Hepatitis C--treatment of untreated (naive) patients].
Duvnjak M; Pavić T; Tomasić V; Lerotić I; Virović L
Acta Med Croatica; 2005; 59(5):453-61. PubMed ID: 16381243
[TBL] [Abstract][Full Text] [Related]
22. The use of different Peg-interferon alpha-2b regimens plus ribavirin in HCV-1b-infected patients after rapid virological response does not affect the achievement of sustained virological response.
Napoli N; Giannelli G; Antonaci A; Antonaci S
J Viral Hepat; 2008 Apr; 15(4):300-4. PubMed ID: 18307592
[TBL] [Abstract][Full Text] [Related]
23. Clinical and histological efficacy of pegylated interferon and ribavirin therapy of recurrent hepatitis C after liver transplantation.
Fernández I; Meneu JC; Colina F; García I; Muñoz R; Castellano G; Fuertes A; Abradelo M; Lumbreras C; Moreno E; Solís-Herruzo JA
Liver Transpl; 2006 Dec; 12(12):1805-12. PubMed ID: 17133585
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of peg-IFN alfa-2a with ribavirin for the treatment of HCV/HIV coinfected patients who failed previous IFN based therapy.
Rodríguez-Torres M; Rodríguez-Orengo JF; Ríos-Bedoya CF; Fernández-Carbia A; González-Lassalle E; Salgado-Mercado R; Marxuach-Cuétara AM
J Clin Virol; 2007 Jan; 38(1):32-8. PubMed ID: 17064957
[TBL] [Abstract][Full Text] [Related]
25. Comparison of a 6-month course peginterferon alpha-2b plus ribavirin and interferon alpha-2b plus ribavirin in treating Chinese patients with chronic hepatitis C in Taiwan.
Lee SD; Yu ML; Cheng PN; Lai MY; Chao YC; Hwang SJ; Chang WY; Chang TT; Hsieh TY; Liu CJ; Chen DS
J Viral Hepat; 2005 May; 12(3):283-91. PubMed ID: 15850469
[TBL] [Abstract][Full Text] [Related]
26. Adherence to treatment for recently acquired hepatitis C virus (HCV) infection among injecting drug users.
Grebely J; Matthews GV; Hellard M; Shaw D; van Beek I; Petoumenos K; Alavi M; Yeung B; Haber PS; Lloyd AR; Kaldor JM; Dore GJ;
J Hepatol; 2011 Jul; 55(1):76-85. PubMed ID: 21145855
[TBL] [Abstract][Full Text] [Related]
27. Recruitment and follow-up of injecting drug users in the setting of early hepatitis C treatment: insights from the ATAHC study.
Nguyen OK; Dore GJ; Kaldor JM; Hellard ME;
Int J Drug Policy; 2007 Oct; 18(5):447-51. PubMed ID: 17854736
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of a 24-week course of PEG-interferon alpha-2b monotherapy in patients with acute hepatitis C after failure of spontaneous clearance.
Santantonio T; Fasano M; Sinisi E; Guastadisegni A; Casalino C; Mazzola M; Francavilla R; Pastore G
J Hepatol; 2005 Mar; 42(3):329-33. PubMed ID: 15710214
[TBL] [Abstract][Full Text] [Related]
29. A short course of pegylated interferon-alpha in acute HCV hepatitis.
Calleri G; Cariti G; Gaiottino F; De Rosa FG; Bargiacchi O; Audagnotto S; Quaglia S; De Blasi T; Romano P; Traverso A; Leo G; Carbone R; Del Mastro B; Tinelli M; Caramello P; Di Perri G
J Viral Hepat; 2007 Feb; 14(2):116-21. PubMed ID: 17244251
[TBL] [Abstract][Full Text] [Related]
30. Twelve-week treatment of acute hepatitis C virus with pegylated interferon- alpha -2b in injection drug users.
De Rosa FG; Bargiacchi O; Audagnotto S; Garazzino S; Cariti G; Calleri G; Lesioba O; Belloro S; Raiteri R; Di Perri G
Clin Infect Dis; 2007 Sep; 45(5):583-8. PubMed ID: 17682992
[TBL] [Abstract][Full Text] [Related]
31. Pegylated interferon alpha-2b in patients with acute hepatitis C.
Mukhopadhyay A
Natl Med J India; 2006; 19(4):201-2. PubMed ID: 17100108
[No Abstract] [Full Text] [Related]
32. Pegylated interferon α-2b plus ribavirin for Japanese chronic hepatitis C patients with normal alanine aminotransferase.
Kainuma M; Furusyo N; Azuma K; Kajiwara E; Takahashi K; Nomura H; Tanabe Y; Satoh T; Maruyama T; Nakamuta M; Kotoh K; Shimoda S; Hayashi J;
Hepatol Res; 2012 Jan; 42(1):33-41. PubMed ID: 22103907
[TBL] [Abstract][Full Text] [Related]
33. Interferon therapy for acute hepatitis C viral infection--a review by meta-analysis.
Quin JW
Aust N Z J Med; 1997 Oct; 27(5):611-7; discussion 617-8. PubMed ID: 9404604
[TBL] [Abstract][Full Text] [Related]
34. Cellular immune responses during high-dose interferon-alpha induction therapy for hepatitis C virus infection.
Barnes E; Gelderblom HC; Humphreys I; Semmo N; Reesink HW; Beld MG; van Lier RA; Klenerman P
J Infect Dis; 2009 Mar; 199(6):819-28. PubMed ID: 19434929
[TBL] [Abstract][Full Text] [Related]
35. Treatment of chronic hepatitis C in injecting drug users: 5 years' follow-up.
Dalgard O; Bjøro K; Hellum K; Myrvang B; Skaug K; Gutigard B; Bell H;
Eur Addict Res; 2002 Jan; 8(1):45-9. PubMed ID: 11818693
[TBL] [Abstract][Full Text] [Related]
36. Barriers to interferon-alpha therapy are higher in intravenous drug users than in other patients with acute hepatitis C.
Broers B; Helbling B; François A; Schmid P; Chuard C; Hadengue A; Negro F;
J Hepatol; 2005 Mar; 42(3):323-8. PubMed ID: 15791696
[TBL] [Abstract][Full Text] [Related]
37. Treatment of chronic hepatitis D with interferon alpha-2b in patients with human immunodeficiency virus infection.
Puoti M; Rossi S; Forleo MA; Zaltron S; Spinetti A; Putzolu V; Rodella A; Carosi G
J Hepatol; 1998 Jul; 29(1):45-52. PubMed ID: 9696491
[TBL] [Abstract][Full Text] [Related]
38. Approaching treatment for hepatitis C virus infection in substance users.
Sylvestre DL
Clin Infect Dis; 2005 Jul; 41 Suppl 1():S79-82. PubMed ID: 16265620
[TBL] [Abstract][Full Text] [Related]
39. Optimizing assessment and treatment for hepatitis C virus infection in illicit drug users: a novel model incorporating multidisciplinary care and peer support.
Grebely J; Knight E; Genoway KA; Viljoen M; Khara M; Elliott D; Gallagher L; Storms M; Raffa JD; DeVlaming S; Duncan F; Conway B
Eur J Gastroenterol Hepatol; 2010 Mar; 22(3):270-7. PubMed ID: 20425880
[TBL] [Abstract][Full Text] [Related]
40. Outcomes from a large 10 year hepatitis C treatment programme in people who inject drugs: No effect of recent or former injecting drug use on treatment adherence or therapeutic response.
Elsherif O; Bannan C; Keating S; McKiernan S; Bergin C; Norris S
PLoS One; 2017; 12(6):e0178398. PubMed ID: 28636638
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
